Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 5/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | F12 | P00748 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | STS | P08842 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24469902 | 0.89 | NAMPT (0.40) | P2RX3MAPK1F12PARP1TNKS2 | |
| SCHEMBL24469807 | 0.83 | P2RX3 (0.43) | P2RX3HDAC1HDAC6MAPK1F12 | |
| SCHEMBL24484074 | 0.75 | NAMPT (0.40) | P2RX3MAPK1F12PARP1TNKS2 | |
| SCHEMBL29670401 | 0.75 | NAMPT (0.40) | P2RX3MAPK1F12PARP1TNKS2 | |
| SCHEMBL1622628 | 0.73 | HTR2C (0.56) | P2RX3PARP1TNKS2PARP2STS | |
| SCHEMBL22717415 | 0.73 | GPR119 (0.42) | P2RX3F12PARP1TNKS2PARP2 | |
| SCHEMBL22845220 | 0.72 | ABHD6 (0.39) | P2RX3F12PARP1TNKS2PARP2 | |
| SCHEMBL17325153 | 0.72 | ALDH1A1 (0.44) | P2RX3HDAC1HDAC6MAPK1PARP1 | |
| SCHEMBL2076077 | 0.71 | HDAC1 (0.48) | P2RX3HDAC1HDAC6MAPK1PARP1 | |
| SCHEMBL2270578 | 0.70 | PARP1 (0.57) | MAPK1PARP1TNKS2PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20220169650-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169650-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | P2RX3 3237/4885HDAC1 47/4885HDAC6 12/4885 |
| US-11820773-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | P2RX3 3237/4885HDAC1 47/4885HDAC6 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.